Clinical Trials Logo

Clinical Trial Summary

Alzheimer's disease (AD) is the most common dementia and has been one of the most expensive diseases with the highest lethality. With the rapid increase of the aging population, more and more burdens will be posed on society and economics. The manifestations of AD are the progressive loss of memory, language and visuospatial function, executive and daily living abilities, and so forth. The Pathophysiological changes of AD occur 10-20 years before the clinical symptoms, while there is still a lack of effective strategy for early diagnosis. Mild cognitive impairment (MCI) is considered to be a transitional state between healthy aging and the clinical diagnosis of dementia and has received increasing attention as a separate diagnostic entity. To make the diagnosis, doctors ought to compressively consider the multimodal medical information including clinical symptoms, neuroimages, neuropsychological tests, laboratory examinations, etc. Multimodal deep learning has risen to this challengeļ¼Œ which could integrate the various modalities of biological information and capture the relationships among them contributing to higher accuracy and efficiency. It has been widely applied in imaging, tumor pathology, genomics, etc. Recently, the studies on AD based on deep learning still mainly focused on multimodal neuroimaging, while multimodal medical information requires comprehensive integration and intellectual analysis. Moreover, studies reveal that some imperceptible symptoms in MCI and the early stage of AD may also play an effective role in diagnosis and assessment, such as gait disorder, facial expression identification dysfunction, and speech and language impairment. However, doctors could hardly detect the slight and complex changes, which could rely on the full mining of the video and audio information by multimodal deep learning. In conclusion, we aim to explore the features of gait disorder, facial expression identification dysfunction, and speech and language impairment in MCI and AD, and analyze their diagnostic efficiency. We would identify the different degrees of dependency on multimodal medical information in diagnosis and finally build an optimal multimodal diagnostic method utilizing the most convenient and economical information. Besides, based on follow-up observations on the changes in multimodal medical information with the progress of AD and MCI, we expect to establish an effective and convenient diagnostic strategy.


Clinical Trial Description

Our objective is to make the early diagnosis and assessment of AD and MCI based on multimodal deep learning. Initially, Gait disorder, facial expression identification dysfunction, and speech and language impairment are of great significance in the occurrence and development of AD and MCI. However, due to the high complexity and stealthiness of these clinical symptoms, no uniform conclusions have been made. Hence, we attempt to apply machine learning methods to recognize the video and audio information. In this way, we will explore the changing characteristics of gait, expression, and language in AD and MCI, and analyze their diagnostic effectiveness as diagnostic markers, finally providing new ideas and experimental data for the diagnosis of AD and MCI. Secondly, multimodal medical information needs to be integrated and comprehensively analyzed. We aim to propose an optimal diagnostic strategy referring to the different degrees of dependency on multimodal medical information in diagnosis. Moreover, observing the changes in multimodal medical information with the progress of AD and MCI, we expect to build a predicting model of AD diagnosis and prognosis. The methods are as follows: 1. Collecting multimodal medical information A variety of multimodal medical information would be carefully collected including the baseline demographic data, chief complaint and medical history, peripheral organ function assessment, laboratory examination, imaging examination, neuroelectrophysiological examination, neurocognitive and psychological examination, information on gait, expression, and language, and biological samples, etc. 2. Revealing the changes of gait, expression, and language in patients with AD and MCI, and verifying their diagnostic efficacy. For multimodal medical information on gait, OpenPose model was used to extract human key points and construct a human skeleton structure diagram. Based on graph neural networks and convolutional neural networks, instantaneous action analysis of single-frame images is carried out. And then utilizing the Transformer model, gait sequence analysis is carried out by integrating multi-frame video.For multimodal medical information on facial expression, the Dlib algorithm will be used to extract facial key points, combined with facial expression images, and the spatiotemporal Transformer model will be used for facial expression analysis. For multimodal medical information on language, ASRT model will be used for speech recognition and text content extraction. Simultaneously, the frequency domain Fourier transform and wavelet transform will be applied to extract frequency domain information and analyze the speech features by integrating language content, voice intonation, speech speed, and other information. Based on the attention model, the gait, expression, and language analysis results of AD and MCI will be compared with those of the control group to reveal the features of AD and MCI and provide evidence for disease diagnosis. 3. Analyzing the different degrees of dependency on multimodal information in the diagnosis of AD and MCI diseases, and establishing an optimal diagnosis strategy In the supervised learning process, the attention mechanism-based method will be used to analyze the influence of multimodal information on the final results. At the same time, based on the knowledge map, the patient's blood biochemical indicators, genomic information and other fields of knowledge would be added to the model. Based on Bayesian probability inference and causal inference theory, the causal programming method will be used to model the causal analysis of information and diagnosis results of different modes. Based on AutoML method, multimodal information will be combined and optimized, and a reliable optimal diagnosis strategy will be established according to experimental results. 4. Exploring the changes of multimodal medical information with the progression of the disease, and build a predicting model for early diagnosis and disease progression of AD. Viewing multimodal medical information as the control condition, the Transformer model will be used to model time sequence information, and the conditional diffusion model will be used to generate patients' MRI image changes and other disease progression-related information, providing the basis for disease progression prediction. Based on the large multimodal model technology, the output of the model will be interfered with and adjusted referring to the judgment and description of professional doctors, to generate the prediction in line with the judgment of professional doctors, and finally construct the interpretable early diagnosis and disease progression prediction model. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06081569
Study type Observational
Source First Hospital of China Medical University
Contact Huayan Liu, PhD.
Phone +86 13609831417
Email liuhy@cmu1h.com
Status Not yet recruiting
Phase
Start date October 15, 2023
Completion date October 15, 2026

See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A